Surgery

• DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.
• The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously a DermTech employee, as inducements material to the employee’s entering into employment with DermTech, in accordance with Nasdaq Listing Rule 5635(c)(4).
• The 26,240 restricted stock units shall vest over 4 years as follows: (i) twenty-five percent of the restricted stock units will vest on March 5, 2025 and (ii) the remaining seventy-five percent of the restricted stock units will vest in equal quarterly installments until fully vested on March 5, 2028, subject to the employee’s continued employment with the Company on these vesting dates.
• The restricted stock units are also subject to the terms and conditions of the 2022 Inducement Plan and the terms and conditions of the equity award agreements covering the grants.

• Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
• Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
• Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
• Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

• Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.
• Glaukos will be exhibiting onsite at booth #631.
• The faculty includes Ike Ahmed, MD (Moderator); Sahar Bedrood, MD; John Berdahl, MD; Manjool Shah, MD; and Blake Williamson, MD.
• The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.

Tenet Healthcare Corporation (NYSE: THC) will release its first quarter 2024 results on Tuesday, April 30, 2024, no later than 6:00 a.m. Central Time (CT), to be followed by a conference call at 9:00 a.m. CT (10:00 a.m. Eastern Time).